BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 23523787)

  • 21. Cell type-dependent regulation of hMLH1 promoter activity is influenced by the presence of multiple redundant elements.
    Warnick CT; Dabbas B; Ilstrup SJ; Ford CD; Strait KA
    Mol Cancer Res; 2003 Jun; 1(8):610-8. PubMed ID: 12805408
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The role of EZH2 and DNA methylation in the silencing of the tumour suppressor RUNX3 in colorectal cancer.
    Kodach LL; Jacobs RJ; Heijmans J; van Noesel CJ; Langers AM; Verspaget HW; Hommes DW; Offerhaus GJ; van den Brink GR; Hardwick JC
    Carcinogenesis; 2010 Sep; 31(9):1567-75. PubMed ID: 20631058
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A change in promoter methylation of hMLH1 is a cause of acquired resistance to platinum-based chemotherapy in epithelial ovarian cancer.
    Watanabe Y; Ueda H; Etoh T; Koike E; Fujinami N; Mitsuhashi A; Hoshiai H
    Anticancer Res; 2007; 27(3B):1449-52. PubMed ID: 17595760
    [TBL] [Abstract][Full Text] [Related]  

  • 24. MicroRNA-101 inhibits growth of epithelial ovarian cancer by relieving chromatin-mediated transcriptional repression of p21(waf¹/cip¹).
    Semaan A; Qazi AM; Seward S; Chamala S; Bryant CS; Kumar S; Morris R; Steffes CP; Bouwman DL; Munkarah AR; Weaver DW; Gruber SA; Batchu RB
    Pharm Res; 2011 Dec; 28(12):3079-90. PubMed ID: 21818714
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comprehensive analysis of promoter methylation and altered expression of hMLH1 in gastric cancer cell lines with microsatellite instability.
    Kang YH; Bae SI; Kim WH
    J Cancer Res Clin Oncol; 2002 Mar; 128(3):119-24. PubMed ID: 11935297
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cancer-associated fibroblasts enhance the migration ability of ovarian cancer cells by increasing EZH2 expression.
    Xu L; Deng Q; Pan Y; Peng M; Wang X; Song L; Xiao M; Wang Z
    Int J Mol Med; 2014 Jan; 33(1):91-6. PubMed ID: 24212330
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Increased microsatellite instability and epigenetic inactivation of the hMLH1 gene in head and neck squamous cell carcinoma.
    Zuo C; Zhang H; Spencer HJ; Vural E; Suen JY; Schichman SA; Smoller BR; Kokoska MS; Fan CY
    Otolaryngol Head Neck Surg; 2009 Oct; 141(4):484-90. PubMed ID: 19786217
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Head and neck squamous cell carcinoma: mismatch repair immunohistochemistry and promoter hypermethylation of hMLH1 gene.
    Tawfik HM; El-Maqsoud NM; Hak BH; El-Sherbiny YM
    Am J Otolaryngol; 2011; 32(6):528-36. PubMed ID: 21353335
    [TBL] [Abstract][Full Text] [Related]  

  • 29. DNA hypomethylation-mediated activation of Cancer/Testis Antigen 45 (CT45) genes is associated with disease progression and reduced survival in epithelial ovarian cancer.
    Zhang W; Barger CJ; Link PA; Mhawech-Fauceglia P; Miller A; Akers SN; Odunsi K; Karpf AR
    Epigenetics; 2015; 10(8):736-48. PubMed ID: 26098711
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Aberrant methylation of hMLH1 gene promoter in papillary thyroid cancer and its clinical significance].
    Lu XX; Ge MH; Ling ZQ; Hu SS; Xu J; Zheng CM; Tan Z; Chen C
    Zhonghua Zhong Liu Za Zhi; 2013 Nov; 35(11):833-6. PubMed ID: 24447481
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mutually exclusive promoter hypermethylation patterns of hMLH1 and O6-methylguanine DNA methyltransferase in colorectal cancer.
    Fox EJ; Leahy DT; Geraghty R; Mulcahy HE; Fennelly D; Hyland JM; O'Donoghue DP; Sheahan K
    J Mol Diagn; 2006 Feb; 8(1):68-75. PubMed ID: 16436636
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evaluation of microsatellite instability, MLH1 expression and hMLH1 promoter hypermethylation in colorectal carcinomas among Tunisians patients.
    Kria Ben Mahmoud L; Arfaoui A; Khiari M; Chaar I; Lounis A; Sammoud S; Ben Hmida AM; Gharbi L; Mzabi SR; Bouraoui S
    Tunis Med; 2012; 90(8-9):646-53. PubMed ID: 22987381
    [TBL] [Abstract][Full Text] [Related]  

  • 33. hMLH1 and MGMT inactivation as a mechanism of tumorigenesis in monoclonal gammopathies.
    Martin P; Santón A; García-Cosio M; Bellas C
    Mod Pathol; 2006 Jul; 19(7):914-21. PubMed ID: 16607377
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mismatch repair gene expression defects contribute to microsatellite instability in ovarian carcinoma.
    Geisler JP; Goodheart MJ; Sood AK; Holmes RJ; Hatterman-Zogg MA; Buller RE
    Cancer; 2003 Nov; 98(10):2199-206. PubMed ID: 14601090
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Methylation in hMLH1 promoter interferes with its binding to transcription factor CBF and inhibits gene expression.
    Deng G; Chen A; Pong E; Kim YS
    Oncogene; 2001 Oct; 20(48):7120-7. PubMed ID: 11704838
    [TBL] [Abstract][Full Text] [Related]  

  • 36. miR-101 regulates expression of EZH2 and contributes to progression of and cisplatin resistance in epithelial ovarian cancer.
    Liu L; Guo J; Yu L; Cai J; Gui T; Tang H; Song L; Wang J; Han F; Yang C; Chen C; Marks A; Wang Z
    Tumour Biol; 2014 Dec; 35(12):12619-26. PubMed ID: 25260883
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The acquisition of hMLH1 methylation in plasma DNA after chemotherapy predicts poor survival for ovarian cancer patients.
    Gifford G; Paul J; Vasey PA; Kaye SB; Brown R
    Clin Cancer Res; 2004 Jul; 10(13):4420-6. PubMed ID: 15240532
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Expression of the hMLH1 gene is a possible predictor for the clinical response to 5-fluorouracil after a surgical resection in colorectal cancer.
    Ide T; Kitajima Y; Ohtaka K; Mitsuno M; Nakafusa Y; Miyazaki K
    Oncol Rep; 2008 Jun; 19(6):1571-6. PubMed ID: 18497967
    [TBL] [Abstract][Full Text] [Related]  

  • 39. EZH2 blockade by RNA interference inhibits growth of ovarian cancer by facilitating re-expression of p21(waf1/cip1) and by inhibiting mutant p53.
    Seward S; Semaan A; Qazi AM; Gruzdyn OV; Chamala S; Bryant CC; Kumar S; Cameron D; Sethi S; Ali-Fehmi R; Morris R; Bouwman DL; Munkarah AR; Weaver DW; Gruber SA; Batchu RB
    Cancer Lett; 2013 Aug; 336(1):53-60. PubMed ID: 23603558
    [TBL] [Abstract][Full Text] [Related]  

  • 40. EZH2-mediated epigenetic silencing of TIMP2 promotes ovarian cancer migration and invasion.
    Yi X; Guo J; Guo J; Sun S; Yang P; Wang J; Li Y; Xie L; Cai J; Wang Z
    Sci Rep; 2017 Jun; 7(1):3568. PubMed ID: 28620234
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.